SQZ Biotechnologies (NYSE:SQZ) Expected to Post Quarterly Sales of $4.17 Million

Wall Street brokerages predict that SQZ Biotechnologies (NYSE:SQZGet Rating) will post sales of $4.17 million for the current fiscal quarter, Zacks Investment Research reports. Three analysts have issued estimates for SQZ Biotechnologies’ earnings, with the lowest sales estimate coming in at $3.00 million and the highest estimate coming in at $4.92 million. SQZ Biotechnologies reported sales of $4.54 million in the same quarter last year, which indicates a negative year over year growth rate of 8.1%. The firm is scheduled to announce its next earnings results on Monday, January 1st.

On average, analysts expect that SQZ Biotechnologies will report full year sales of $30.56 million for the current year, with estimates ranging from $12.87 million to $57.61 million. For the next financial year, analysts anticipate that the business will post sales of $33.30 million, with estimates ranging from $21.00 million to $40.00 million. Zacks’ sales averages are an average based on a survey of analysts that follow SQZ Biotechnologies.

SQZ Biotechnologies (NYSE:SQZGet Rating) last issued its quarterly earnings data on Tuesday, May 10th. The company reported ($0.75) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.69) by ($0.06). SQZ Biotechnologies had a negative net margin of 303.43% and a negative return on equity of 57.79%.

NYSE SQZ opened at $3.50 on Monday. SQZ Biotechnologies has a one year low of $2.73 and a one year high of $16.17. The business’s fifty day moving average is $4.06 and its 200-day moving average is $7.34. The stock has a market capitalization of $98.52 million, a price-to-earnings ratio of -1.33 and a beta of 3.73.

Several institutional investors have recently made changes to their positions in the stock. Citigroup Inc. raised its stake in shares of SQZ Biotechnologies by 139.6% in the third quarter. Citigroup Inc. now owns 2,595 shares of the company’s stock worth $37,000 after buying an additional 1,512 shares during the period. Royal Bank of Canada increased its stake in SQZ Biotechnologies by 96.2% in the 3rd quarter. Royal Bank of Canada now owns 3,059 shares of the company’s stock worth $44,000 after acquiring an additional 1,500 shares during the last quarter. UBS Group AG boosted its holdings in shares of SQZ Biotechnologies by 85.8% in the 3rd quarter. UBS Group AG now owns 7,000 shares of the company’s stock worth $101,000 after purchasing an additional 3,233 shares during the period. Metropolitan Life Insurance Co NY purchased a new position in SQZ Biotechnologies during the 3rd quarter valued at $104,000. Finally, Bangor Savings Bank purchased a new position in SQZ Biotechnologies during the 4th quarter valued at $99,000. Institutional investors own 66.56% of the company’s stock.

About SQZ Biotechnologies (Get Rating)

SQZ Biotechnologies Company, a clinical-stage biotechnology company, develops cell therapies for patients with cancer, autoimmune, infectious diseases, and other serious conditions. Its lead product candidate is SQZ-PBMC-HPV, from its SQZ Antigen Presenting Cells platform, which is in a Phase I clinical trial as a monotherapy and in combination with other immuno-oncology agents for the treatment of HPV16+ advanced or metastatic solid tumors, including cervical, head-and-neck, anal, penile, vulvar, and vaginal cancer.

Featured Stories

Get a free copy of the Zacks research report on SQZ Biotechnologies (SQZ)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for SQZ Biotechnologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SQZ Biotechnologies and related companies with MarketBeat.com's FREE daily email newsletter.